Congenital Myasthenic Syndrome 7 C4015038
A genetic disorder affecting the neuromuscular junction. It causes muscle weakness that appears in infancy or early childhood. Medication and supportive care can help improve symptoms.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigable muscle weakness
(neurologic)Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Dysphagia
(neurologic)Respiratory insufficiency
(neurologic)Joint contractures
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Ephedrine
Sympathomimetic agent that can improve muscle strength in CMS type 7 by enhancing neuromuscular transmission through adrenergic mechanisms.
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Albuterol
Beta-2 agonist bronchodilator that may provide symptomatic improvement in some CMS type 7 patients by affecting neuromuscular junction function.
Additional treatment options
Environmental Modification
Adapting home and work environments to reduce physical demands, including grab bars, wheelchair accessibility, and positioning aids to minimize energy expenditure.
lifestyleAcupuncture Adjunctive Therapy
Traditional acupuncture may provide supportive benefit for fatigue management and muscle relaxation as part of a comprehensive treatment approach.
complementarySerial Strength Assessment
Regular quantitative strength testing using standardized tools to track disease progression and treatment response over time.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Congenital Myasthenic Syndrome 7 C4015038?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Beeson D, Higuchi O, Palace J, et al. Dok7 Mutations and Congenital Myasthenic Syndromes: A Comprehensive Review. Neuromuscul Disord. 2020.
International Consensus Guidance for Management of Congenital Myasthenic Syndromes. Neurology. 2021.
Muller JS, Hantan D, Wroe P, et al. Clinical Features and Molecular Characterization of Dok7-Related Congenital Myasthenic Syndrome. Brain. 2019.
Chester M, Farrugia ME, McMacken G, et al. Treatment Outcomes in Congenital Myasthenic Syndrome: A Systematic Review and Meta-Analysis. Ann Neurol. 2022.
Medication Comparisons
Compare medications used to treat Congenital Myasthenic Syndrome 7 C4015038. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy